Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Next Previous
Search
Trial Profile

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EIK 1001 (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Cholangiocarcinoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms EIK1001
  • Sponsors Birdie Biopharmaceuticals; Eikon Therapeutics

Most Recent Events

  • 26 Mar 2025 Status changed from active, no longer recruiting to completed.
  • 04 Jun 2024 Results (n=51) assessing safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 28 May 2024 According to an Eikon Therapeutics media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago May 31-June 4, 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top